$0.55 EPS Expected for Haemonetics Co. (HAE) This Quarter

Wall Street analysts expect that Haemonetics Co. (NYSE:HAE) will announce earnings per share (EPS) of $0.55 for the current quarter, according to Zacks. Four analysts have issued estimates for Haemonetics’ earnings. The highest EPS estimate is $0.57 and the lowest is $0.52. Haemonetics posted earnings of $0.43 per share during the same quarter last year, which would suggest a positive year over year growth rate of 27.9%. The company is expected to announce its next quarterly earnings results on Tuesday, May 14th.

On average, analysts expect that Haemonetics will report full-year earnings of $2.33 per share for the current year, with EPS estimates ranging from $2.30 to $2.35. For the next financial year, analysts expect that the company will post earnings of $2.79 per share, with EPS estimates ranging from $2.61 to $2.90. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Haemonetics.

Haemonetics (NYSE:HAE) last posted its earnings results on Tuesday, February 5th. The medical instruments supplier reported $0.63 EPS for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.04. Haemonetics had a net margin of 4.84% and a return on equity of 17.05%. The company had revenue of $247.36 million for the quarter, compared to analysts’ expectations of $250.12 million. During the same quarter in the prior year, the company posted $0.62 earnings per share. Haemonetics’s revenue for the quarter was up 5.7% compared to the same quarter last year.

A number of research firms have commented on HAE. Barrington Research upped their target price on shares of Haemonetics to $112.00 and gave the company a “positive” rating in a research report on Wednesday, February 6th. ValuEngine cut shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 5th. Finally, Zacks Investment Research raised shares of Haemonetics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 30th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $119.75.

In other news, VP Dan Goldstein sold 1,693 shares of the stock in a transaction dated Monday, December 10th. The shares were sold at an average price of $102.91, for a total transaction of $174,226.63. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Jacqueline Scanlan sold 1,027 shares of the stock in a transaction dated Wednesday, December 12th. The stock was sold at an average price of $104.22, for a total transaction of $107,033.94. The disclosure for this sale can be found here. Insiders have sold 10,916 shares of company stock worth $1,124,301 in the last three months. Corporate insiders own 1.04% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Haemonetics by 1.6% during the fourth quarter. BlackRock Inc. now owns 6,026,806 shares of the medical instruments supplier’s stock worth $602,982,000 after purchasing an additional 92,894 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Haemonetics by 1.9% during the third quarter. Vanguard Group Inc. now owns 5,619,707 shares of the medical instruments supplier’s stock worth $643,906,000 after purchasing an additional 107,357 shares in the last quarter. Vanguard Group Inc lifted its position in shares of Haemonetics by 1.9% during the third quarter. Vanguard Group Inc now owns 5,619,707 shares of the medical instruments supplier’s stock worth $643,906,000 after purchasing an additional 107,357 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Haemonetics by 14.6% during the third quarter. Renaissance Technologies LLC now owns 2,256,500 shares of the medical instruments supplier’s stock worth $258,550,000 after buying an additional 286,800 shares during the period. Finally, Jackson Square Partners LLC increased its stake in shares of Haemonetics by 15.6% during the third quarter. Jackson Square Partners LLC now owns 1,439,167 shares of the medical instruments supplier’s stock worth $164,899,000 after buying an additional 194,045 shares during the period. 97.54% of the stock is currently owned by institutional investors and hedge funds.

NYSE HAE traded up $1.83 during trading hours on Monday, reaching $88.00. The company had a trading volume of 657,340 shares, compared to its average volume of 493,533. Haemonetics has a 1-year low of $68.84 and a 1-year high of $117.56. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.44 and a quick ratio of 1.64. The stock has a market capitalization of $4.49 billion, a P/E ratio of 47.06, a PEG ratio of 2.74 and a beta of 0.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Story: Key terms to understand channel trading

Get a free copy of the Zacks research report on Haemonetics (HAE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply